<DOC>
	<DOC>NCT00887341</DOC>
	<brief_summary>This 2 arm study will compare the incidence of tocilizumab-related infusion reactions, using 2 different infusion times, in patients with moderate to severe rheumatoid arthritis who have shown an inadequate response to DMARDs (Disease Modifying Anti Rheumatic Drugs) or anti-TNFs.Patients will be randomized to one of 2 groups, to receive tocilizumab 8mg/kg iv every 4 weeks either a)over a 1h infusion time for all administrations or b) a 1h infusion time for the first administration, followed by a 31 minute infusion time for subsequent administrations (unless drug-related infusion reactions occur).The anticipated time on study treatment is 3-12 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; active moderate or severe rheumatoid arthritis; active disease for &gt;6 months; inadequate response to a stable dose of nonbiologic DMARDs or antiTNFs. rheumatic autoimmune disease other than rheumatoid arthritis; prior history of, or current inflammatory joint disease other than rheumatoid arthritis; major surgery (including joint surgery) within 8 weeks prior to screening, or planned major surgery within 6 months following enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>